參考文獻(xiàn)/References:
[1] SALAMANCA-FERNáNDEZ E,RODRIGUEZ-BARRANTO M,CHANG-CHAN YL,et al. Thyroid cancer epidemiology in South Spain: a population-based time trend study[J].Endocrine,2018,62(2): 423-431.
[2] DCRUZ A K,VAISH R,VAIDYA A,et al. Molecular markers in well-differentiated thyroid cancer[J].Eur Arch Otorhinolaryngol,2018,275(6): 1375-1384.
[3] LI D,WANG Q,LI N,ZHANG S. miR-205 targets YAP1 and inhibits proliferation and invasion in thyroid cancer cells[J].Mol Med Rep,2018,18(2): 1674-1681.
[4] HE Y,YU D,ZHU L,ZHONG S,et al. miR-149 in human cancer: a systemic review[J].J Cancer,2018,9(2): 375-388.
[5] XIA F,WANG W,JIANG B,et al. DNA methylation-mediated silencing of miR-204 is a potential prognostic marker for papillary thyroid carcinoma[J].Cancer Manag Res,2019,11: 1249-1262.
[6] BAO P P,ZHENG Y,WU C X,et al. Cancer incidence in urban Shanghai,1973-2010: an updated trend and age-period-cohort effects[J].BMC Cancer,2016,16: 284.
[7] SISSON J C,FREITAS J,MCDOUGALL I R,et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association[J].Thyroid,2011,21(4): 335-346.
[8] DETTMER M S,PERREN A,MOCH H,et al. MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights[J].J Mol Endocrinol,2014,52(2): 181-189.
[9] DAMANAKIS A I,ECKHARDT S,WUNDERLICH A,et al. MicroRNAs let7 expression in thyroid cancer: correlation with their deputed targets HMGA2 and SLC5A5[J].J Cancer Res Clin Oncol,2016,142(6): 1213-1220.
[10] LEE Y S,LIM Y S,LEE J C,et al. Differential expression levels of plasma-derived miR-146b and miR-155 in papillary thyroid cancer[J].Oral Oncol,2015,51(1): 77-83.
[11] HAN P A,KIM H S,CHO S,et al. Association of BRAF V600E mutation and MicroRNA expression with central lymph node metastases in papillary thyroid cancer: a prospective study from four endocrine surgery centers[J].Thyroid,2016,26(4): 532-542.
[12] MAURER U,CHARVET C,WAGMAN A S,et al. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1[J].Mol Cell,2006,21(6): 749-760.
[13] FAN S J,LI H B,CUI G,et al. miRNA-149* promotes cell proliferation and suppresses apoptosis by mediating JunB in T-cell acute lymphoblastic leukemia[J].Leuk Res,2016,41: 62-70.
[14] XU K,LIU X,MAO X,et al. MicroRNA-149 suppresses colorectal cancer cell migration and invasion by directly targeting forkhead box transcription factor FOXM1[J].Cell Physiol Biochem,2015,35(2): 499-515.
[15] LUO K,HE J,YU D,et al. MiR-149-5p regulates cisplatin chemosensitivity,cell growth,and metastasis of oral squamous cell carcinoma cells by targeting TGFβ2[J].Int J Clin Exp Pathol,2019,12(10): 3728-3739.
[16] DOHáN O,DE LA V A,PARODER V,et al. The sodium/iodide Symporter(NIS): characterization,regulation,and medical significance[J].Endocr Rev,2003,24(1): 48-77.
[17] SANTHANAM P,SOLNES L B,ROWE S P. Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond[J].Med Oncol,2017,34(12): 189.
[18] SPITZWEG C,BIBLE K C,HOFBAUER L C,et al. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets[J].Lancet Diabetes Endocrinol,2014,2(10): 830-842.
[19] ANDERSON R T,LINNEHAN J E,TONGBRAM V,et al. Clinical,safety,and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review[J].Thyroid,2013,23(4): 392-407.
[20] JIA L,CHEN Y,CHEN F,et al. Small activating RNA-activated NIS gene promotes 131I uptake and inhibits thyroid cancer via AMPK/mTOR pathway[J].Pathol Res Pract,2022,229: 153735.